Lung Cancer: From Molecular Mechanisms to Novel Therapeutics: 2nd Edition
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 30 September 2025 | Viewed by 349
Special Issue Editors
2. Department of Human Pathology “G. Barresi”, University of Messina, Messina, Italy
Interests: lung cancer; targeted therapy; immunotherapy; personalized medicine; biomarkers
Special Issues, Collections and Topics in MDPI journals
2. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
Interests: lung cancer; mesothelioma; targeted therapy; immunotherapy; biomarkers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the continuation of our Special Issue “Lung Cancer: From Molecular Mechanisms to Novel Therapeutics”.
Lung cancer remains the most significant cause of cancer-related deaths worldwide. Both molecular-targeted therapy and immunotherapy have revolutionized the diagnostic and therapeutic management of this heterogeneous disease, which includes different histologic and molecular subtypes. The number of actionable oncogenic drivers continues to expand in parallel with the development of novel targeted agents. On the other hand, several immune checkpoint inhibitors, as single agents or in combinatorial regimens, have been approved in metastatic non-small-cell lung cancer without targetable molecular alterations because of the demonstration of significant clinical efficacy and manageable toxicity profiles. Their development has been shifted in the early stages, with promising results. However, despite significant therapeutic advances, several challenges still remain, including the need for additional reliable biomarkers to select patients for immunotherapy and a better understanding of the complex biologic mechanisms leading to therapeutic resistance. This Special Issue will focus on (a) identification of new druggable driver gene alterations in lung cancer; (b) development of new drugs and combination therapies targeting specific molecular pathways; (c) current knowledge on primary and secondary mechanisms of resistance to targeted therapies or immunotherapy; and (d) current and emerging techniques to identify predictive biomarkers in tissue and liquid biopsy.
Dr. Mariacarmela Santarpia
Dr. Giulia Pasello
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- oncogene
- targeted therapy
- immunotherapy
- predictive biomarkers
- liquid biopsy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
